NeOnc Technologies(NASDAQ) NTHI

Neonc develops new ways to deliver drugs for brain diseases. Its main products aim to help people with aggressive brain cancers. These treatments use non-invasive methods to reach the brain more effectively.

Brainy Business: Products and Services

• NEO100 (0% revenue): Intranasal drug for recurrent brain cancers, in Phase IIa trials, targets glioblastoma and meningioma patients.
• NEO212 (0% revenue): Oral therapy combining two drugs; oral version completed early testing and is in clinical trials for primary and secondary brain tumors, while intranasal version is still in preclinical development.
• Drug Delivery Platform (0% revenue): Technology to deliver other drugs to the brain, including for Parkinson’s disease, still in early development.
• AI and 3D Bioprinting (0% revenue): Tools for drug discovery and disease modeling, used internally for research.
• Other POH Conjugates (0% revenue): Early-stage molecules for future brain disease treatments, not yet in clinical trials.

Plot Twists: Growth and Expansion

• Acquired AI and 3D bioprinting technology in 2025 for $3.5 million.
• Entered into a letter of intent in 2025 to form a joint venture with Quazar Investment Group for Middle East clinical trials.
• Expanded NEO100 clinical trials to include meningioma in 2023.
• Completed Phase I trial for NEO212 in 2025, planning further studies.
• Secured multiple NIH grants totaling $1.4 million (pending as of end 2025).

What Makes Neonc Stand Out

Neonc uses intranasal and intra-arterial drug delivery to bypass the blood-brain barrier, a major challenge in brain disease treatment. Its AI and 3D bioprinting platforms help speed up drug discovery and reduce animal testing. The company holds exclusive licenses for its core technologies and partners with global firms for clinical development.

Five Things You Need to Know

• Revenue was $39,990 in 2025, down 52% from 2024, all non-recurring.
• Operating expenses rose to $58.3 million in 2025, up 710% from 2024.
• Net loss reached $62.1 million in 2025, up 422% from 2024.
• Cash balance was $58,729 at December 31, 2025, with $16 million raised in March 2026.
• Auditors flagged “going concern” risk due to recurring losses and low cash reserves.

Bottom Line

Neonc focuses on new drug delivery methods for brain diseases and relies on external funding. The company faces high costs, early-stage products, and significant financial risks as it develops its pipeline.